Table 4.
Baseline characteristics
| MT (n = 382) | RYGB (n = 388) | SG (n = 201) | P | |
|---|---|---|---|---|
| Female | 276 (72,3) | 301 (77,6) | 152 (75,6) | 0.206 |
| Age (years) | 49.0 (18–78) | 43.5 (18–62) | 41 (18–63) | < 0.0001 |
| BMI (kg/m2) | 40.1 (31.6–90.4) | 41.8 (34.8–65.3) | 41.6 (35–63.7) | < 0.0001 |
| HbA1c (mmol/mol) | 36 (25.0–95.0) | 37 (26–118) | 36 (27–73) | 0.173 |
| HDL (mmol/l) | 1.3 (0.6–2.6) | 1.2 (0.4–2.3) | 1.2 (0.7–2.0) | 0,003 |
| LDL (mmol/l) | 3.1 (1.2–6.7) | 3.2 (0.8–6.2) | 3.3 (0.9–5.7) | 0.627 |
| Glucose lowering treatment | 55 (14,4) | 55 (14,2) | 28 (13,9) | 0.990 |
| Blood pressure lowering treatment | 135 (35,3) | 112 (28,9) | 58 (28,9) | 0.109 |
| Lipid lowering treatment | 52 (13,6) | 51 (13,1) | 23 (11,4) | 0.768 |
| Treatment for anxiety/depression | 85 (22,3) | 68 (17,5) | 52 (25,9) | 0.101 |
| Treatment with antipsychotics | 13 (3,4) | 4 (1,0) | 6 (3,0) | 0.078 |
| Pain medication | 80 (20,9) | 63 (16,2) | 38 (18,9) | 0.238 |
| Hypothyroidism treatment | 49 (12,8) | 42 (10,8) | 26 (12,9) | 0.613 |
| ADHD treatment | 8 (2,1) | 2 (0,5) | 2 (1) | 0.124 |
| Iron supplements | 5 (1,3) | 3 (0,8) | 3 (1,5) | 0.685 |
| B-vitamin supplements | 14 (3,7) | 9 (2,3) | 9 (4,5) | 0.313 |
| D-vitamin supplements | 3 (0,8) | 7 (1,8) | 4 (2,0) | 0.347 |
| Folic acid supplements | 6 (1,6) | 4 (1,0) | 6 (3,0) | 0.221 |
| Calcium supplements | 6 (1,6) | 1 (0,3) | 0 (0) | 0.055 |
| Protonpump inhibitor treatment | 50 (13,1) | 39 (10,1) | 30 (14,9) | 0.180 |
| Education | 0.082 | |||
| Elementary | 51 (13,4) | 42 (10,8) | 15 (7,5) | |
| Secondary | 141 (36,9) | 199 (51,3) | 98 (48,8) | |
| Tertiary | 127 (33,2) | 101 (26,0) | 69 (34,3) | |
| Smoking | 23 (6,0) | 24 (6,2) | 13 (6,5) | 0.884 |
| Married/cohabitation | 206 (53,9) | 242 (62,4) | 121 (60,2) | 0.955 |
Data are n (%) or median (range)
MT Medical treatment, GBP Roux-en-Y gastric bypass, SG Sleeve gastrectomy, BMI Body mass index, HDL High-density lipoprotein, LDL Low-density lipoprotein